

**DOCKET NO.: 133087.10701 (101340-1P US/CV)**

**PATENT**

**RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP NO. 1624**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of: Alenfalk, Dahlström, Hunegnaw, Karlsson, Lemurell, Lindqvist,  
Skjäret, and Starke**

**Title: Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory  
Activity**

**Serial No.: 10/596,731**

**Group Art Unit: 1624**

**Filed: November 16, 2006**

**Examiner: Mark L. Berch**

**Confirmation No.: 9947**

**Filed by EFS Web on: 17 May 2010**

**Mail Stop AF**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**RESPONSE UNDER 37 C.F.R. §1.116**

In response to the Final Rejection dated May 3, 2010 in regard to the above-identified patent application, Applicants respectfully request that the application be amended as follows.

Amendment of the claims begins at page 2.

Remarks begin at page 12.